Llusern Scientific was born from a shared desire to make a difference. Our point-of-care testing technology consists of a unique swabbing method, a one-tube molecular LAMP reaction and a user-friendly, affordable, portable electronic reader device. Our technology was originally developed for the diagnosis of Urinary Tract Infections (UTIs) but we responded to need during the COVID-19 pandemic and our first product on the market is a test for the accurate detection of SARS-CoV-2.
About Us
Our Story
Llusern’s co-founders all met while working at the University of South Wales. The story began back in 2016 when the team received seed funding from the Longitude Prize for their work on UTIs. Between them, they have over 50 years experience in molecular biology, microbiology and biomedical engineering. Our story continues to unfold… follow our journey here.
Our Vision
Our vision is to be a part of the change to a world where anyone, anywhere has access to accurate diagnostic testing and appropriate treatment. No-one should die from a preventable disease.
Our Mission
Our mission is to reduce existing barriers to accurate diagnostic tools – working with our partners to bring diagnostic testing out of the highly specialised lab environment and truly to point-of-care – in any environment
Core Team
Dr Jeroen Nieuwland
Co-founder
Dr Emma Hayhurst
Co-founder
Dr Ali Roula
Co-founder
Advisory Board
Mark Helmich
Mark Helmich is Managing Director at GX Group
Deborah Komianos
Regional Director and Veterinary Surgeon at CVS (UK) Ltd.
Nanette Bartram
Biotechnology and diagnostic consultant at BIC Innovation Ltd